News

Challenges negatively influenced career satisfaction with 39% seriously considering leaving residency and 30% reporting advising a female medical student against pursuing a surgical career.

A 40-year old patient at the UNC Clinical and Translational Research Center was treated with SB-913 this week.

The survey estimates from the National Center for Health Statistics report that more people are vaccinating for flu and testing for HIV.

The physician community on Twitter is a vibrant, diverse one. But the platform's use in and out of the clinic is still subject to debate.

There were no differences in anxiety and depression scores between perinatally-acquired HIV and HIV-affected participants.

Hormone therapy taken soon after menopause may help prevent memory loss.

A genetic mutation that has previously been linked to Parkinson’s disease and Alzheimer’s disease could also be connected to ALS, according to a team of researchers supported by the National Institute of Health.

With the approval, the syringe becomes the first with anti-VEGF agent approved by the FDA for use to treat DR and DME.

A one-month antibiotic regimen for TB is as effective for patients with HIV as the standard nine-month treatment.

The therapy was approved on the evidence of a pivotal phase 3 clinical development program which tested the efficacy of the inhibitor versus placebo in 926 adult patients.

Positive data from a Phase 3 study of inotersen (IONIS-TTRx) in patients with hereditary ATTR amyloidosis was presented at the 2018 American College of Cardiology Annual Meeting.

The U.S. FDA has granted Pedmark, a unique combination of cisplatin and sodium thiosulfate, Fast Track designation for the prevention of cisplatin-related ototoxicity in pediatric patients with standard risk hepatoblastoma.

In this video, Beth Stein, M.D., and myasthenia gravis patient Anaya Mitchell discuss mestinon, steroids, and other treatment methods for myasthenia gravis.

Pregnant women with polycystic ovary syndrome taking metformin were 5% less likely to experience a miscarriage or preterm birth compared to those on placebo.

Older or immunocomprimized patients incur a large healthcare resource burden with C. difficile.

This research contradicts previous TDF studies that were not placebo-controlled.

This is the first and only FDA-approved gene therapy for treatment for an inherited disease.

If approved, NTX-011 may help combat the nationwide opioid epidemic.

The U.S. FDA has approved brentuximab vedotin (Adcetris) in combination with chemotherapy for adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma.

These findings could be the first step in the design of therapies that are better able to target specific receptors to exert therapeutic effects.

In this video, Beth Stein, M.D. and myasthenia gravis patient Anaya Mitchell explain how raising awareness is changing the landscape for patients with myasthenia gravis and leading to medical breakthroughs for the patient population.

The anti-VEGF marketed as EYLEA has new phase 3 study results in its ongoing trial for NPDR consideration.

Foveomacular, juxta-macular, and peripheral retina punch biopsies can be used to determine protein levels and identify patterns of expression.

Many studies have already shown that short-term exposure to fine particle pollution can have a negative effect on lung function, but just 2 exist on the long-term effects, with inconsistent results.

It was announced this morning that dasiglucagon has met its primary and key secondary objectives in its multinational Phase 3 clinical trial in patients with severe hypoglycemia.

While not the preferred solution, choroidal neovascularization removal in patients with AMD can be useful in specific circumstances.

The odds of reaching undetectable HCV RNA by 12 weeks were 57% less for African-Americans in the retrospective study.

The president's remarks in New Hampshire Monday called for judicial action and a law enforcement-centric approach to the opioid epidemic.

This morning, Cellectar Biosciences announced that the U.S. FDA has granted orphan drug designation to CLR 131 for the treatment of neuroblastoma.

The U.S. FDA granted Fast Track designation to nintedanib for the treatment of systemic sclerosis with associated interstitial lung disease (SSc-ILD).